biologic

Novolog

insulin aspart

Loss of exclusivityJanuary 2013projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameNovolog
Active ingredientinsulin aspart
Strength300UNITS/3ML (100UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJanuary 2001
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Novolog patent cliff — loss of exclusivity January 2013 | CliffBio